Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2026
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.
Journal: Neuro-oncology
Published: March 09, 2026
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Journal: ESMO open
Published: October 03, 2025
Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30.
Journal: Neuro-oncology
Published: August 29, 2025
Reflecting on Scientific Growth and Innovation as the Society for Neuro-Oncology Turns 30.
Journal: Neuro-oncology
Published: August 29, 2025
Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).
Journal: Medical sciences (Basel, Switzerland)
Published: July 28, 2025
Molecularly driven therapies in the treatment of primary brain tumors.
Journal: Advances in cancer research
Published: July 17, 2025
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS.
Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort.
Journal: Neuro-oncology advances
Published: May 13, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 18, 2025
Last Updated: 09/26/2026